Key points are not available for this paper at this time.
Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression.
Building similarity graph...
Analyzing shared references across papers
Loading...
Kidney International Reports
Peking University
Shanghai Jiao Tong University
Fudan University
Add This Paper to Your Research Feed
Any time a new paper drops it will be there.
Lv et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: